Grupo Alter

With more than 75 years of dedication to health care, Grupo Alter enters the 21st century with the firm conviction that success lies in three basic principles: Innovation, Quality and Service. Our focus on innovation has led us to establish strategic alliances with other companies of great reputation to offer innovative added value products. In addition to strict quality controls established at all levels, our aim for excellence is at the forefront of external and internal audits that all our departments must periodically comply with. We understand service not only as an extension of Innovation and Quality, but as a factor that interacts with both in order to achieve Global Excellence. At Grupo Alter we distribute our products throughout all continents thanks to our own factories throughout Spain as well as our commercial delegations in Portugal, Italy, France and the Dominican Republic. One of the objectives of our Company is to grow and be more competitive within a business environment in constant movement. In order to achieve this we look for the best talent to join our Company. We aim to develop and build a strong team with high levels of professional skills. We are committed to internal promotion and helping our people grow through continuous training and support. In addition to the quality of our products and the effectiveness of our strategies, in the end, our team of professionals are high performers that achieve strong results. "The most extraordinary thing is to do the ordinary well"​

Grupo Indukern

El Grupo Indukern está constituido por las empresas Indukern S.A, Laboratorios Calier S.A., Kern Pharma S.L. y sus respectivas filiales. Su actividad está diversificada en tres actividades principales: - Distribución de productos Químicos. - Investigación, fabricación y comercialización de productos de uso veterinario. - Desarrollo, fabricación y comercialización de genéricos. Con un volumen de ventas alrededor de los 600 millones de Euros se caracteriza por su diversidad de productos, amplia presencia internacional y su constante estrategia emprendedora.

HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention for animal and human health, with a broad range of highly innovative vaccines and an advanced diagnostic service. A company that works with the latest technological advances to create innovative solutions that improve world health. R&D projects are the basis of the knowledge. HIPRA has more than 50 years of experience dedicated to the research and development of different vaccines. With a unique organizational model, HIPRA controls all the processes of the value chain, generating singular know-how and becoming a reference in the research, production, and commercialization of biologics. HIPRA has a solid international presence, commercial subsidiaries and a global distribution network, allowing products to reach costumers from more than 100 countries, covering the 5 continents.

SAMI Pharmaceuticals (Pvt.) Ltd.

SAMI Pharmaceuticals is one of the fastest growing pharmaceutical companies in Pakistan. Our success is driven by the hard work of our employees, who are among the best people in the industry. We strive hard to train and develop the best talent, and ensure that our growth as a company is correlated with our employees’ growth as individuals.

Fagron

Fagron is committed to the personalization of health treatment to cover the individual patient’s need through Pharmaceutical Compounding & Sterile Outsourcing Services. Pharmaceutical Compounding allows pharmacists and prescribers to create medication that satisfies patients’ needs. Through our services towards personalization, we can extend the range of mass-produced medication and keep available medicaments that are no longer offered commercially in an affordable way for those who need them. Fagron was founded in the Netherlands in 1990 and is currently present in 35 countries worldwide enabling pharmacists, prescribers, hospitals, and industry to provide quality, safety, and service for their patients. Together we create the future of personalizing medicine.